Forma Therapeutics Secures $25M in Private Funds to Buy Discovery Tools

January 07, 2009

By Ben Butkus

Forma Therapeutics, a drug-discovery company co-founded by scientists from the Broad Institute, has secured an initial $25 million in equity and non-dilutive funding to assemble a drug-discovery toolbox from several academic and corporate entities – although the Broad Institute is not among those potential licensors.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.

In this issue of Biotech Transfer Week

Young Investigator Profile

Sumit Chanda

Associate Professor
Sanford-Burnham Medical Research Institute

Unraveling Complex Host-Pathogen

The Chanda lab is studying cellular proteins required for both influenza A and retrovirus/HIV infection as well as novel molecules that regulate, or respond to, Pattern Recognition Receptor (PRR) signaling. In order to elucidate the repertoire of host proteins required for viral infection, and understand the molecular strategies adapted by these viruses as countermeasures to innate immune response, his lab uses a series of systems-level approaches, including genome-wide RNAi, proteomics and protein-protein interaction (PPI) analysis, and high content imaging. This approach is helping them to build a comprehensive cellular 'roadmap' exploited by these viruses to enable their propagation within a cell.
Blog

Who Knew Genetic Test Anxiety Is So Prevalent? New Screen Aims to ID the Distressed

Researchers have taken to dealing with pre-genetic-testing anxieties on a clinical level by developing a screening tool to identify individuals who may need additional post-test counseling.

March 17, 2010

A Night to Get Out the Vogt

Cancer researchers celebrate Peter Vogt, winner of this year's Szent-Györgyi Prize.

March 17, 2010

The Human Genome Bubble

The human genome bubble led to technological advances, researchers say.

March 17, 2010

Cellular Defect Could Lead to Cancer

Researchers have discovered a cellular defect in some people that could make them more susceptible to cancer.

March 17, 2010
Papers of Note

Regulation and Function of miR-218 in Gastric Cancer Metastasis
Tie, Pan et al., PLoS Genetics
Researchers describe a negative feedback system between Robo1, a Slit receptor, and miR-218, wherein “decreased miR-218 levels eliminate Robo1 repression, which activates the Slit-Robo1 pathway through the interaction between Robo1 and Slit2, thus triggering tumor metastasis.” The authors suggest that the restoration of miR-218 supresses Robo1 espression and inhibits tumor cell invasion.

Method to Label and Isolate N-terminal Peptides from Human Plasma
Wildes and Wells, PNAS
A pair of researchers report their method to “dramatically reduce the complexity” of human serum samples by eliminating internal peptides. The authors write that, with their method, it's possible to identify substrates from specific proteases with the exogenous addition of the protease along with N-terminal isolation and quantitative mass spectrometry.
People on the Move

Wellcome Trust Sanger Institute Professor Leena Peltonen-Palotie died this week of cancer at her home in Finland, according to the Sanger Institute. Peltonen-Palotie was head of human genetics at Wellcome Trust, and she held appointments at the Broad Institute at MIT and Harvard and the Institute for Molecular Medicine Finland.

Three leaders from the Human Genome Project — David Botstein, Francis Collins, and Eric Lander — have been named co-winners of the 2010 Albany Medical Center Prize in Medicine and Biomedical Research, which carries with it a purse of $500,000.

Adrian Dillon will resign from his job as executive VP of finance and administration and CFO of Agilent Technologies to become chief financial and administrative officer at Skype. He will be replaced at the beginning of April by Didier Hirsch, who currently is VP of corporate controllership and taxes and who will serve as acting CFO.
Upcoming Events

Conferences, Meetings & Deadlines

PTEN Pathways & Targets
Mar. 16-20 / Cold Spring Harbor, NY
CSHL

The Complex Life of mRNA: From Synthesis to Decay
Mar. 18-19 / Heidelberg, Germany
EMBL

Perspectives in Clinical Proteomics
Mar. 18-19 / Hinxton, UK
EMBL-EBI-Wellcome Trust

AUTM 2010 Annual Meeting
Mar. 18-20 / New Orleans, La.
Association of University Technology Managers

ABRF 2010
Mar. 20-23 / Sacramento, CA
Association of Biomolecular Resource Facilities

Abstract & Registration Deadlines

more

Science
Researchers from the Institute for Systems Biology and elsewhere used Complete Genomics' sequencing service to identify mutations behind a Mendelian condition called Miller syndrome and an inherited lung disorder called ciliary dyskinesia in a family of four.
Business
Bruker will acquire certain mass spectrometry and chromatography product lines from Varian, clearing the way for Agilent to complete its $1.5 billion acquisition of Varian. The divestitures were part of conditions set by EU authorities for approval of the merger.
Funding
HHS expects that in 2010 NIH will spend another roughly $5.2 billion overall in stimulus funds that were left over from ARRA's first year. NIH still has more than $1.6 billion to spend in stimulus funds for lab construction and renovation, buildings and facilities, and shared instruments.
Genome Technology Magazine
Check out this month's humor page here:

Search

Forma Therapeutics Secures $25M in Private Funds to Buy Discovery Tools

Related Stories

In this issue of Biotech Transfer Week

Young Investigator Profile

Blog

Papers of Note

People on the Move

Upcoming Events

Science

Business

Funding

Genome Technology Magazine

TechGuides Listings

Poll